

COPY

PATENT CASE IN01481K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X	
In re Application of: Anandan Palani et al.	: Examiner: To Be Assigned
For:	: Group Art Unit: 1642
PIPERIDINE DERIVATIVES USEFUL AS	: Attorney Docket No.: IN01481K
CCR5 ANTAGONISTS	: Date: May 28, 2003
Serial No.: 10/229,466	:
Filed: August 28, 2002	: -----X
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450	

INFORMATION DISCLOSURE STATEMENT


Sir:

It is requested that the documents listed on the accompanying PTO Form 1449 be considered and made of record in the above-identified patent application. A copy of each cited document is attached.

A copy of the PCT International Search Report dated November 12, 2002 for corresponding PCT Application No. PCT/US02/27389 is submitted for the Examiner's review.


The Commissioner is authorized to charge Deposit Account No. 19-0365 for any additional fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

Respectfully submitted,


Robert L. Bernstein
Reg. No. 46,020
Attorney for Applicants
(908) 298-3985

Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, New Jersey 07033

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450 ON May 28, 2003 (DATE OF DEPOSIT) Robert L. Bernstein REG. NO. 46,020 (REGISTERED REPRESENTATIVE)


(SIGNATURE AND DATE)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of: :
Anandan Palani et al :
: :
For Patent For: Examiner: To Be Assigned
PIPERIDINE DERIVATIVES USEFUL :
AS CCR5 ANTAGONISTS : Art Unit: To Be Assigned
: :
Serial No.: To Be Assigned : Date: July 29, 2003
: :
Filing Date: July 29, 2003
-----X

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Submitted herewith is Applicants' PTO 1449 form, and a copy of Applicants' Information Disclosure Statement from Applicants' parent Application Serial No. 10/229,466 filed August 28, 2002.

The references cited in the present PTO 1449 form were cited in the PTO 1449 form submitted in Applicants' parent Application, with the exception of Reference AK which is a newly cited reference.

Since the cited references were cited in Applicants' parent Application, copies of the references are not being submitted herewith. The Examiner is requested to notify the undersigned if another copy of the references is desired.

Applicant requests that the cited documents be made of record in the above-identified Application.

Respectfully submitted,

7/29/03
Date

Robert L. Bernstein
Robert L. Bernstein
Reg. No. 46,020
Attorney for Applicants

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.: IN01481KC APPLICANT: Anandan Palani et al. FILING DATE: July 23, 2003		SERIAL NO.: To Be Assigned GROUP: To Be Assigned		
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	5,952,349	09/14/99	Theodros Asberom et al.	514	316	
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
AK	WO 02/081449	10/17/02	PCT	C07D	211/58	
AL	WO 98/01425	01/15/98	PCT	C07D	211/58	
AM	EP 0 855 999	10/04/01	Europe	C07D	211/44	
AN	WO 97/24324	07/10/97	PCT	C07D	211/44	
AO	EP 0 151 824	08/21/85	Europe	C07D	471/04	
AP	WO 01/30348	05/03/01	PCT	A61K	31/445	
AQ	WO 01/77101	10/18/01	PCT	C07D	401/04	
AR	WO 02/081449	10/17/02	PCT	C07D	211/58	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
AS	Anandan Palani et al., "Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxyimino)methyl]-1'-[(2,4--dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine N-Oxide (SCH 351125): An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection", Journal of Medicinal Chemistry, vol. 44, No. 21, October 11, 2001, pgs. 3339-3342					
AT						
AU						
AV						
AW						
AX						
EXAMINER			DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						